Day One Biopharmaceuticals, Inc.
DAWN
$7.46
$0.497.03%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2,190.50% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,190.50% | -- | -- | -- | -- |
| Cost of Revenue | 1,487.13% | -- | -- | -- | -- |
| Gross Profit | 2,256.94% | -- | -- | -- | -- |
| SG&A Expenses | 20.39% | 40.61% | 52.83% | 53.91% | 39.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.24% | 59.25% | 66.66% | 62.93% | 66.56% |
| Operating Income | 61.14% | 13.70% | -3.01% | -9.07% | -61.94% |
| Income Before Tax | 46.12% | 70.36% | 53.23% | 52.08% | 0.14% |
| Income Tax Expenses | 260.31% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 43.28% | 66.94% | 49.45% | 51.70% | -0.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.28% | 66.94% | 49.45% | 51.70% | -0.79% |
| EBIT | 61.14% | 13.70% | -3.01% | -9.07% | -61.94% |
| EBITDA | 62.11% | 14.74% | -2.27% | -8.59% | -61.80% |
| EPS Basic | 53.48% | 73.65% | 56.61% | 55.62% | 15.45% |
| Normalized Basic EPS | 54.51% | 75.98% | 62.08% | 58.51% | 18.73% |
| EPS Diluted | 53.43% | 73.57% | 56.57% | 55.46% | 15.23% |
| Normalized Diluted EPS | 54.44% | 75.93% | 62.02% | 58.45% | 18.73% |
| Average Basic Shares Outstanding | 17.08% | 16.56% | 16.91% | 17.19% | 19.55% |
| Average Diluted Shares Outstanding | 17.17% | 16.66% | 17.01% | 17.29% | 19.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |